Hagop M. Kantarjian MD FASCO

PubMed

• Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.
  Daniel J DeAngelo, Ying Chen, Ryan D Cassaday, Jennifer E Hibma, Derek Z Yang
  Leukemia & Lymphoma. 2026-08-18
• Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.
  Aziz Farhat, Georgina El Hajjar, Hagop Kantarjian, Koji Sasaki, Nicholas J Short
  Cancer. 2026-08-15
• Treatment of adult acute lymphoblastic leukemia-a therapeutic revolution in the making.
  Hagop Kantarjian, Ayalew Tefferi
  Blood Cancer Journal. 2026-08-05

Journal Articles

• Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor Therapy  
  Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Blood
• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood

Books/Book Chapters

• Harrison's Principles of Internal Medicine 
  Chapter: Chronic Myeloid Leukemia 
  Page 687 - 695Kantarjian H, Cortes JEditors: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J.McGraw Hill, Chicago, IL2015
• The Molecular Basis of Cancer 
  Chapter: Biology of Adult Myelocytic Leukemia and Myelodysplasia 
  Page 421 - 432Post S, Kantarjian H, Quintas-Cardama AEditors: Mendelsohn J, Gray J, Howley P, Israel M, Thompson C.Elsevier Saunders, Philadelphia, PAEdition 4th,2014
• Cancer Consult Expertise for Clinical Practice 
  Chapter: Management of B-cell acute lymphoblastic leukemia 
  Page 22 - 28Ghanem H, Kantarjian H, Jain N, Jabbour EEditors: Syed A. Abutalib, Maurie Markman.John Wiley and Sons, Inc., Hoboken, NJEdition 1st,2014

Abstracts/Posters

• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
  Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Medical Crossfire¬: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia _ How the Experts Think and Treat 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a l... 
  2019 ASCO Annual Meeting - 6/1/2019

Other

• Health Care in the U.S. Should be a Basic Human Right, not an Entitlement 
  Jones G, Kantarjian H, Baker Institute Blog
  1/1/2015
• What is the 340B Drug Discount Program and why is it so important? 
  Kantarjian H, Chapman R, James A. Baker Institute Blog, Insight and analysis from the James A. Baker III Institute for Public
  Rice University - 1/1/2015
• Insurers Play to Win, but the Patients Lose 
  Jain N, Kantarjian H, The Houston Chronicle Outlook Section
  1/1/2015